It's the thought that Goldman Sachs argues in a Tuesday research report, as others in the pharmaceuticals and healthcare space like Abbott Laboratories (ABT) and Covidien (COV) pursue multi-billion spinoff plans. Already, Pfizer is headed in the direction of consolidation after putting its animal healthcare and baby nutrition units on the selling block.
After meeting with Pfizer Chief Executive Ian Read, Goldman Sachs analyst Jami Rubin says that the world's largest drug maker may take bigger breakup steps than just a sale of its animal health and nutrition units. "We recently met with PFE's CEO Ian Read, who expressed an openness to going further with separations beyond Animal Health and Nutrition if the conditions make sense... This, coupled with the CEO's openness to consider unlocking further value, could create an attractive situation with significant upside," wrote Rubin of the meeting.
If Pfizer were to undergo a full breakup Rubin expects it to occur in three parts, with a previously stated intention to separate the New York-based company's animal health and nutrition units being the first step. In July, CEO Read said that Pfizer was exploring strategic alternatives for its animal health and nutrition units. Recent media reports signal that Danone of France and Mead Johnson (MJN) could bid on Pfizer's nutrition business for $10 billion. March reports also signal that Bayer (BAYRY) could bid up to $18 billion for Pfizer's animal health unit.
Rubin added new twists to Pfizer deal rumors in his report of talks with Read. "Mr. Read believes the most likely scenario to be a sale of Nutritionals and an IPO/split-off of Animal Health, reiterating that "buybacks will be the case to beat," wrote Rubin.In a split, Pfizer would be more focused on its growth oriented pharmaceuticals business and a stable generics business, argues Rubin, who sees the moves netting Pfizer 18 cents a share in earnings per share. A second step would then be a rationalization of Pfizer's organizational structure after the disposals with efficiency efforts likely to wrench out a $26 a share stock value that puts Pfizer on Goldman Sachs' "America's conviction buy list."
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV